Nicholas Sellke1,2,*, Erin Jesse1,2, Justin M. Dubin3, Tomislav D. Medved1,2, Neha S. Basti4, Janvi Ramchandra2, Robert E. Brannigan4, Joshua A. Halpern4, Nannan Thirumavalavan1,2
Canadian Journal of Urology, Vol.32, No.2, pp. 89-94, 2025, DOI:10.32604/cju.2025.065004
- 30 April 2025
Abstract Introduction: Direct-to-consumer (DTC) telemedicine has emerged as an option for transgender patients seeking gender affirming hormone therapy (GAHT). We aimed to characterize the healthcare services provided by DTC telemedicine companies offering GAHT and to compare their costs to a tertiary care center. Methods: We identified DTC telemedicine platforms offering GAHT via internet searches and extracted information from their websites related to evaluation, treatment, monitoring, and cost. Cost of the DTC GAHT was compared to cost for comparable services at a tertiary care center. Results: Six DTC companies were identified. All platforms utilized an informed consent model… More >